hereditary angioedema

Close up shot of the target from a dart game
Biotech

Pharvaris ph. 3 win builds case for HAE drug sitting with FDA

Pharvaris’ deucrictibant has tasted success in a second phase 3 study, strengthening the case for the therapy to treat hereditary angioedema patients.
James Waldron Sep 8, 2026 10:10am
Hurdles lined up on track for race

BioCryst CEO sets out strategy after ending internal discovery

Aug 14, 2026 10:07am
closed close

BioCryst ends internal programs in pivot to partnerships

Jun 29, 2026 10:30am
Eclipse

Intellia touts ‘paradigm-shifting’ HAE data

Jun 15, 2026 10:37am
Hand with tweezers editing DNA

Intellia races in vivo CRISPR therapy to FDA after phase 3 win

Apr 27, 2026 9:24am
An arrow incrementally going up stairs before pointing straight up Blue background

Pharvaris clocks a pivotal win in race for rapid HAE relief

Dec 3, 2025 9:10am